GO:0008489 UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008489 describes the enzymatic activity that transfers galactose from UDP-galactose to glucosylceramide, producing lactosylceramide (LacCer).
• This activity is primarily carried out by beta-1,4-galactosyltransferase V (B4GALT5) and B4GALT6 in humans, and is often referred to as LacCer synthase.
• LacCer, the product of this reaction, is a key glycosphingolipid involved in cell signaling, inflammation, and cancer progression [1, 3].
• The activity is stimulated by oxidized low-density lipoprotein (ox-LDL) and platelet-derived growth factor (PDGF), linking it to atherosclerosis and smooth muscle cell proliferation [2, 4, 6].
• Dysregulation of this activity has been implicated in tumor progression, particularly in proximal tubular cells, and in inflammatory diseases [7, 3].
• Studying this enzyme requires tools such as CRISPR knockout, point mutation, and overexpression models to dissect its role in disease pathways [1, 6].
Description
UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity (GO:0008489) is a molecular function that catalyzes the transfer of galactose from UDP-galactose to glucosylceramide, yielding lactosylceramide (LacCer) and UDP. This reaction is a critical step in the biosynthesis of glycosphingolipids, which are essential components of cell membranes and play key roles in cell recognition, signaling, and adhesion [1, 3]. The enzyme responsible for this activity, often termed LacCer synthase, is a member of the beta-1,4-galactosyltransferase family, with B4GALT5 and B4GALT6 being the primary isoforms in humans. Researchers are interested in this activity because LacCer and its downstream metabolites are involved in a wide range of physiological and pathological processes. For instance, LacCer mediates tumor necrosis factor-alpha (TNF-alpha)-induced intercellular adhesion molecule-1 (ICAM-1) expression and neutrophil adhesion in human umbilical vein endothelial cells, highlighting its role in inflammation. Moreover, oxidized low-density lipoprotein (ox-LDL) stimulates this enzymatic activity, leading to Ras activation, mitogen-activated protein kinase (MAPK) signaling, and c-fos expression in aortic smooth muscle cells, which contributes to atherosclerosis. The activity is also elevated in tumor proximal tubular cells, suggesting a role in cancer. Given its involvement in cancer, inflammation, and cardiovascular disease, understanding the regulation and function of GO:0008489 is of significant biomedical importance. This article provides a comprehensive overview of the enzymatic mechanism, key genes, disease associations, and research methodologies, including CRISPR-based models, to study this activity.
UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity At A Glance
| GO ID | GO:0008489 |
|---|---|
| GO term | UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity |
| Ontology | molecular_function |
| Synonym | LacCer synthase activity, lactosylceramide synthase activity, UDP-galactose glucosylceramide beta-1,4-galactosyltransferase activity |
| Definition | Catalysis of the reaction: a beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine + UDP-alpha-D-galactose = a beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) + H+ + UDP. |
| Major function | Synthesis of lactosylceramide, a precursor for complex glycosphingolipids. |
| Reaction direction | Forward: transfer of galactose from UDP-galactose to glucosylceramide. |
| Substrates | UDP-alpha-D-galactose and glucosylceramide. |
| Products | Lactosylceramide, UDP, and H+. |
| Cellular location | Golgi apparatus membrane. |
What Is GO:0008489?
UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity (GO:0008489) is defined as the catalysis of the reaction: a beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine (glucosylceramide) + UDP-alpha-D-galactose = a beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) (lactosylceramide) + H+ + UDP. In simpler terms, it is the enzyme activity that adds a galactose molecule to glucosylceramide, forming lactosylceramide, a key glycosphingolipid.
Why Is UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity Important in Cell Biology?
GO:0008489 is important because it governs the production of lactosylceramide (LacCer), a central glycosphingolipid that serves as a precursor for more complex gangliosides and is a signaling molecule in its own right. LacCer is implicated in diverse cellular processes, including proliferation, adhesion, and inflammation, and its dysregulation is associated with cancer, atherosclerosis, and inflammatory diseases [1, 3, 7]. Understanding this activity provides insights into disease mechanisms and potential therapeutic targets.
• LacCer, the product of GO:0008489, is a key mediator of TNF-alpha-induced ICAM-1 expression and neutrophil adhesion in endothelial cells, linking it to inflammation.
• Oxidized LDL stimulates this enzymatic activity, leading to Ras activation and MAPK signaling in aortic smooth muscle cells, contributing to atherosclerosis.
• The activity is elevated in tumor proximal tubular cells, suggesting a role in cancer progression.
• Platelet-derived growth factor (PDGF) recruits LacCer to induce cell proliferation in Chinese hamster ovary cells, highlighting its role in growth signaling.
• Oxidized LDL and LacCer both stimulate proliferating cell nuclear antigen (PCNA) expression and proliferation of aortic smooth muscle cells.
• Minimally oxidized LDL contains a biologically active component that stimulates aortic smooth muscle cell proliferation via this activity.
• B4GALT5, one of the enzymes catalyzing this activity, is involved in cancer signaling and inflammation pathways.
• Inhibiting this activity could be a therapeutic strategy for diseases characterized by excessive glycosphingolipid synthesis.
• The activity is essential for the synthesis of complex glycosphingolipids that play roles in cell recognition and signaling.
• Studying this activity helps elucidate the mechanisms of glycosphingolipid-related disorders and identify new drug targets.
What Happens During UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity?
Substrate Recognition and Binding
In simple terms: The enzyme grabs its two starting materials: glucosylceramide and UDP-galactose.
The enzyme, typically B4GALT5 or B4GALT6, resides in the Golgi membrane and binds its substrates: glucosylceramide, a lipid embedded in the membrane, and UDP-galactose, a sugar nucleotide. The binding involves specific domains that recognize the glucose moiety of glucosylceramide and the UDP portion of UDP-galactose.
Catalytic Transfer of Galactose
In simple terms: The enzyme snips off galactose from UDP-galactose and attaches it to glucosylceramide.
In the catalytic step, the enzyme transfers the galactose residue from UDP-galactose to the 4-hydroxyl group of the glucose in glucosylceramide, forming a beta-1,4 linkage. This reaction releases UDP and a proton (H+). The product is lactosylceramide (LacCer), a glycosphingolipid with a galactose-beta-1,4-glucose structure.
Product Release and Downstream Metabolism
In simple terms: The newly made lactosylceramide is released and can be further modified into more complex lipids.
After catalysis, lactosylceramide is released into the Golgi membrane, where it can serve as a substrate for further glycosylation reactions, leading to the synthesis of gangliosides and other complex glycosphingolipids. Lactosylceramide itself can also act as a signaling molecule, influencing pathways such as those involving Ras and MAPK [2, 3].
Regulation by External Stimuli
In simple terms: Outside signals like oxidized LDL or growth factors can turn up the enzyme's activity.
The activity of this enzyme is not constant; it can be stimulated by external factors. For example, oxidized low-density lipoprotein (ox-LDL) increases galactosyltransferase activity in aortic smooth muscle cells, leading to Ras activation and cell proliferation. Similarly, platelet-derived growth factor (PDGF) recruits lactosylceramide to induce proliferation in cells expressing mutant GalT-V. These findings indicate that the enzyme is integrated into cellular signaling networks.
Key Genes Involved in GO:0008489 UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity
The following genes encode enzymes or related proteins that carry out or regulate UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| B4GALT5 | Encodes beta-1,4-galactosyltransferase V, a key enzyme for LacCer synthesis | Implicated in cancer signaling, inflammation, and other disease-centric pathways |
| B4GALT6 | Encodes beta-1,4-galactosyltransferase VI, another enzyme with LacCer synthase activity | May compensate for B4GALT5 loss; potential target in glycosphingolipid disorders |
| UGCG | Encodes glucosylceramide synthase, which produces the substrate glucosylceramide | Upstream of GO:0008489; knockout reduces substrate availability |
| B3GALT4 | Encodes beta-1,3-galactosyltransferase, involved in ganglioside synthesis downstream of LacCer | May influence flux through the LacCer pathway |
| B4GALNT1 | Encodes beta-1,4-N-acetyl-galactosaminyl transferase 1, which uses LacCer as a substrate | Downstream enzyme; its activity depends on LacCer levels |
| ST3GAL5 | Encodes GM3 synthase, which converts LacCer to GM3 ganglioside | Competes with other pathways for LacCer; relevant in ganglioside biology |
| GALC | Encodes galactosylceramidase, which degrades galactosylceramide, not LacCer | Related to sphingolipid metabolism but distinct from GO:0008489 |
| ARSA | Encodes arylsulfatase A, involved in sulfatide metabolism | Indirectly related to glycosphingolipid pathways |
| SMPD1 | Encodes acid sphingomyelinase, which produces ceramide, a precursor to glucosylceramide | Upstream of glucosylceramide synthesis |
| ASAH1 | Encodes acid ceramidase, which hydrolyzes ceramide | Affects ceramide levels and thus glucosylceramide availability |
| CERS2 | Encodes ceramide synthase 2, involved in very long-chain ceramide synthesis | May influence glucosylceramide composition |
| UGCG | Encodes UDP-glucose ceramide glucosyltransferase, the enzyme that adds glucose to ceramide | Directly produces glucosylceramide, the substrate for GO:0008489 |
| LASS1 | Encodes ceramide synthase 1, involved in C18 ceramide synthesis | May affect substrate pool for glucosylceramide |
| SGMS1 | Encodes sphingomyelin synthase 1, which consumes ceramide | Competes with glucosylceramide synthesis |
| SGMS2 | Encodes sphingomyelin synthase 2, another ceramide-consuming enzyme | Affects ceramide availability for glucosylceramide |
| B4GALT1 | Encodes beta-1,4-galactosyltransferase I, which has broader substrate specificity | May exhibit some overlapping activity but distinct from GO:0008489 |
| B4GALT2 | Encodes beta-1,4-galactosyltransferase II | Not known to catalyze GO:0008489 but related family member |
| B4GALT3 | Encodes beta-1,4-galactosyltransferase III | Related family member; substrate specificity differs |
| B4GALT4 | Encodes beta-1,4-galactosyltransferase IV | Related family member; may not act on glucosylceramide |
How Is UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity Regulated?
The activity of UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase is regulated at multiple levels. Transcriptional regulation of B4GALT5 and B4GALT6 can affect enzyme levels. Post-translational modifications and interaction with other proteins may modulate activity. External stimuli such as oxidized LDL and platelet-derived growth factor (PDGF) can rapidly stimulate the activity, leading to increased LacCer synthesis and downstream signaling [2, 6]. Additionally, the availability of substrates (glucosylceramide and UDP-galactose) and the presence of product glycosphingolipids can influence flux through the pathway. However, specific molecular mechanisms of regulation, such as phosphorylation or feedback inhibition, require further investigation.
UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B4GALT5 | Cancer, inflammation | Knockout in cancer cell lines (e.g., HeLa, MCF-7) to assess proliferation and signaling |
| B4GALT5 | Atherosclerosis | Overexpression in smooth muscle cells to study ox-LDL-induced proliferation |
| B4GALT6 | Glycosphingolipid disorders | Knockout in neuronal cells to study ganglioside synthesis |
| UGCG | Gaucher disease, cancer | Knockout to reduce glucosylceramide substrate for GO:0008489 |
| ST3GAL5 | Ganglioside-related disorders | Knock-in of mutations to alter LacCer flux |
Cancer
Elevated activity of UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase and increased LacCer levels have been observed in cancer. In tumor proximal tubular cells, the synthesis of lactosylceramide is upregulated compared to normal cells, suggesting a role in tumorigenesis. B4GALT5, which catalyzes this activity, is implicated in cancer signaling pathways, including those involving Ras and MAPK, which promote cell proliferation and survival [1, 2]. Therefore, targeting this activity could be a potential therapeutic strategy in cancers dependent on glycosphingolipid signaling.
Atherosclerosis and Cardiovascular Disease
Oxidized low-density lipoprotein (ox-LDL) stimulates UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity in aortic smooth muscle cells, leading to increased LacCer synthesis. This, in turn, activates Ras, p44 MAPK, and c-fos, promoting cell proliferation and contributing to the development of atherosclerosis [2, 4]. Minimally oxidized LDL also contains a biologically active component that stimulates smooth muscle cell proliferation via this pathway. Thus, this enzymatic activity is a key mediator of ox-LDL-induced vascular smooth muscle cell proliferation and atherogenesis.
Inflammation
Lactosylceramide, the product of GO:0008489, mediates tumor necrosis factor-alpha (TNF-alpha)-induced intercellular adhesion molecule-1 (ICAM-1) expression and neutrophil adhesion in human umbilical vein endothelial cells. This indicates that the activity plays a role in inflammatory responses by promoting adhesion molecule expression and leukocyte recruitment. Inhibiting this activity might reduce inflammation in conditions such as atherosclerosis and inflammatory bowel disease.
From UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of B4GALT5 reduce LacCer levels and inhibit cancer cell growth? | CRISPR knockout of B4GALT5 in cancer cell lines |
| Does a point mutation in the catalytic domain of B4GALT5 abolish enzymatic activity? | CRISPR point mutation (e.g., D314A) in B4GALT5 |
| Can overexpression of B4GALT5 increase LacCer and promote proliferation? | CRISPR knock-in of a constitutive promoter or overexpression vector |
| Does tagging B4GALT5 with GFP affect its localization and activity? | CRISPR knock-in of GFP tag at the endogenous B4GALT5 locus |
| Does B4GALT6 compensate for B4GALT5 loss? | Double knockout of B4GALT5 and B4GALT6 |
| What is the role of B4GALT5 in ox-LDL-induced signaling? | Knockout of B4GALT5 in aortic smooth muscle cells followed by ox-LDL treatment |
How to Study the UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Conversion of glucosylceramide to lactosylceramide | Measuring basal and stimulated activity in cell lysates |
| CRISPR knockout | Loss of gene function | Assessing the role of B4GALT5 in cancer cell proliferation |
| CRISPR point mutation | Specific amino acid change | Dissecting catalytic residues essential for activity |
| CRISPR knock-in | Addition of tags or reporters | Visualizing enzyme localization in live cells |
| Lipidomics (LC-MS) | Quantification of glycosphingolipids | Profiling LacCer and gangliosides in edited cells |
| RNA-seq | Global gene expression changes | Identifying pathways affected by B4GALT5 knockout |
| Immunofluorescence | Protein localization and expression | Confirming Golgi localization of B4GALT5 |
| Western blot | Protein levels | Validating knockout or overexpression efficiency |
Enzymatic Activity Assays
To directly measure UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity, researchers use in vitro assays with radiolabeled or fluorescent substrates. Typically, cell lysates or membrane fractions are incubated with UDP-[3H]galactose and glucosylceramide, and the formation of radiolabeled lactosylceramide is quantified by thin-layer chromatography or scintillation counting. Such assays have been used to demonstrate stimulation of activity by oxidized LDL in smooth muscle cells.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 is a powerful tool to create knockout, point mutation, and knock-in models for studying GO:0008489. Knockout of B4GALT5 or B4GALT6 can abolish enzyme activity, allowing assessment of downstream effects on LacCer levels and cellular phenotypes. Point mutations in catalytic residues can distinguish enzymatic activity from other functions. Knock-in of tags or reporters enables visualization and tracking of the enzyme. These approaches have been used to study the role of GalT-V in cell proliferation.
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics allows comprehensive analysis of glycosphingolipids, including LacCer and its metabolites. By comparing wild-type and CRISPR-edited cells, researchers can quantify changes in lipid profiles resulting from altered GO:0008489 activity. This method is sensitive and can detect multiple species, providing insights into pathway flux.
RNA Sequencing and Transcriptomics
RNA sequencing can reveal changes in gene expression upon modulation of GO:0008489. For example, knockout of B4GALT5 may lead to compensatory upregulation of other glycosyltransferases or alterations in signaling pathways. Transcriptomic profiling helps identify downstream targets and pathways affected by the activity, as seen in studies linking LacCer to ICAM-1 expression.
How CRISPR Can Be Used to Study GO:0008489 UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity
Knockout
CRISPR knockout of B4GALT5 or B4GALT6 can completely abolish UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity, leading to reduced LacCer levels. This is useful for studying the consequences of loss of function in cancer, inflammation, and atherosclerosis models. For example, knockout of B4GALT5 in cancer cell lines can reveal its role in proliferation and signaling.
Point Mutation
Introducing point mutations in the catalytic domain of B4GALT5 (e.g., replacing a conserved aspartate) can inactivate the enzyme while preserving its structure. This allows researchers to distinguish between enzymatic activity and potential non-catalytic functions. Such mutants have been used to study the role of GalT-V in PDGF-induced proliferation.
Knock-in
Knock-in of a fluorescent tag (e.g., GFP) at the endogenous B4GALT5 locus enables real-time imaging of the enzyme's subcellular localization and dynamics. Knock-in of a promoter or enhancer can also modulate expression levels. These models are valuable for understanding how the enzyme is regulated and trafficked.
Overexpression
Overexpression of B4GALT5 or B4GALT6 using CRISPR activation (CRISPRa) or lentiviral vectors can increase LacCer synthesis and amplify downstream signaling. This is useful for gain-of-function studies, such as assessing the effect of elevated LacCer on cell proliferation and adhesion.
How EDITGENE Supports UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity Research
Researchers studying UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific disease pathway. EDITGENE provides a comprehensive suite of CRISPR-based services to facilitate these investigations, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity research.
Frequently Asked Questions About UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity
What is UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity?
It is an enzymatic activity (GO:0008489) that transfers galactose from UDP-galactose to glucosylceramide, forming lactosylceramide, a key glycosphingolipid.
What genes are involved in UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity?
The primary genes are B4GALT5 and B4GALT6, which encode beta-1,4-galactosyltransferases V and VI, respectively.
What is the role of lactosylceramide in disease?
Lactosylceramide is involved in inflammation, cancer, and atherosclerosis. It mediates TNF-alpha-induced ICAM-1 expression and is elevated in tumor cells [3, 7].
How is UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity regulated?
It is stimulated by oxidized LDL and platelet-derived growth factor, and may be regulated at transcriptional and post-translational levels [2, 6].
What diseases are associated with this activity?
It is associated with cancer, atherosclerosis, and inflammatory diseases [1, 2, 3, 7].
How can I study this activity in the lab?
You can use enzymatic assays, CRISPR knockout/knock-in models, lipidomics, and RNA-seq to measure activity and downstream effects [1, 2, 6].
What is the difference between B4GALT5 and B4GALT6?
Both catalyze the same reaction, but they may have different tissue distributions and regulation. B4GALT5 is more widely studied in cancer and inflammation.
Can I use CRISPR to knockout B4GALT5?
Yes, CRISPR knockout of B4GALT5 is a common approach to study loss of LacCer synthesis and its effects on cell behavior.
What are the substrates of this enzyme?
The substrates are UDP-galactose and glucosylceramide.
What is the product of this reaction?
The product is lactosylceramide (LacCer), along with UDP and H+.
Conclusion
UDP-galactose:glucosylceramide beta-1,4-galactosyltransferase activity (GO:0008489) is a critical enzymatic step in glycosphingolipid biosynthesis, producing lactosylceramide, a molecule with diverse roles in cell signaling, inflammation, and cancer. The activity is primarily mediated by B4GALT5 and B4GALT6 and is stimulated by factors such as oxidized LDL and PDGF. Dysregulation of this activity has been linked to atherosclerosis, cancer, and inflammatory diseases, making it a potential therapeutic target. Advances in CRISPR-based genome editing and lipidomics provide powerful tools to dissect its function and regulation. EDITGENE offers a range of services to support research on this important enzyme activity.
References
- 1. Chatterjee S et al.. 2023. Central Role of β-1,4-GalT-V in Cancer Signaling, Inflammation, and Other Disease-Centric Pathways.. Int J Mol Sci 25(1) PMID: 38203654
- 2. Chatterjee S et al.. 1997. Oxidized low density lipoproteins stimulate galactosyltransferase activity, ras activation, p44 mitogen activated protein kinase and c-fos expression in aortic smooth muscle cells.. Glycobiology 7(5):703-10 PMID: 9254052
- 3. Bhunia AK et al.. 1998. Lactosylceramide mediates tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 (ICAM-1) expression and the adhesion of neutrophil in human umbilical vein endothelial cells.. J Biol Chem 273(51):34349-57 PMID: 9852101
- 4. Chatterjee S et al.. 1996. Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation.. Glycobiology 6(3):303-11 PMID: 8724138
- 5. Chatterjee S et al.. 2004. Identification of a biologically active component in minimally oxidized low density lipoprotein (MM-LDL) responsible for aortic smooth muscle cell proliferation.. Glycoconj J 20(5):331-8 PMID: 15229397
- 6. Kolmakova A et al.. 2005. Platelet derived growth factor recruits lactosylceramide to induce cell proliferation in UDP Gal:GlcCer: beta1 --> 4Galactosyltransferase (GalT-V) mutant Chinese hamster ovary cells.. Glycoconj J 22(7-9):401-7 PMID: 16311884
- 7. Chatterjee S. 1993. Regulation of synthesis of lactosylceramide in normal and tumor proximal tubular cells.. Biochim Biophys Acta 1167(3):339-44 PMID: 8481397
- 8. Chatterjee S. 1997. Oxidized low density lipoproteins and lactosylceramide both stimulate the expression of proliferating cell nuclear antigen and the proliferation of aortic smooth muscle cells.. Indian J Biochem Biophys 34(1-2):56-60 PMID: 9343929
